1 l as RET oncoproteins found in patients with multiple endocrine neoplasia type 2A and 2B (2A/RET and

2 de the dominantly inherited cancer syndromes multiple endocrine neoplasia types 2A and 2B (MEN 2A and

3  Experience with management of patients with multiple endocrine neoplasia types 2A and 2B and with fa

4 , breast cancer, acute myelogenous leukemia, multiple endocrine neoplasia types 2A and 2B, and famili

5  been described as the following phenotypes: multiple endocrine neoplasia type 2A (MEN 2A) and multip

6                The majority of patients with multiple endocrine neoplasia type 2A (MEN2A) and familia

7                                              Multiple endocrine neoplasia type 2A (MEN2A) is predispo

8 esponsible for the inherited cancer syndrome multiple endocrine neoplasia type 2A (MEN2A).

9 en identified as the aetiological factor for multiple endocrine neoplasia type 2A (MEN2A).

10                                Patients with Multiple Endocrine Neoplasia type 2A should have parathy